First Cancer Patient Treated Using RefleXion’s Scintix Radiotherapy

RefleXion Medical, a therapeutic oncology company, has treated its first patient with Scintix biology-guided radiotherapy on the RefleXion X1 PET-CT machine. Scintix therapy is a radiopharmaceutical-directed treatment for early and late-stage cancers. The modality uses a single radiotracer injection to transform cancer cells into real-time biological beacons, which uses the individual biology of each tumor to drive its own treatment by controlling external-beam radiotherapy delivery to multiple tumors. The RefleXion X1 PET-CT machine with Scintix therapy is a hybrid platform that uses both biologic technology for tumors in motion and anatomic capabilities through X1’s fan-beam kVCT.

In February, the biology-guided radiotherapy was FDA cleared to treat patients with lung and bone tumors — these “tumors may arise from primary cancers or from metastatic lesions spread from other cancers in the body,” according to RefleXion. Prior to the February clearance, Scintix was also designated as a Breakthrough Device for lung tumor treatment due to its potential to “precisely manage tumor motion.”

The first patient was treated at Stanford Medicine Cancer Center and, over the coming weeks, other cancer centers in the United States will also begin offering the therapy, including City of Hope Comprehensive Cancer Center in Southern California, and sites in Pennsylvania and Texas. Additionally, Scintix therapy will be available in New Jersey, Connecticut, and Oregon by the end of 2023, according to the company.

For more information on Radiopharmaceuticals, click: The Supply and Availability of Radiopharmaceuticals